<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03738865</url>
  </required_header>
  <id_info>
    <org_study_id>XSGP-304</org_study_id>
    <nct_id>NCT03738865</nct_id>
  </id_info>
  <brief_title>G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes</brief_title>
  <official_title>G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Empiristat, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, controlled, single-blind, two-way crossover efficacy and
      safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime
      clinical research center (CRC) visits with random assignment to receive G-Pen glucagon 1 mg
      during one period and Novo Glucagon 1 mg during the other. Each daytime visit is preceded by
      an overnight stay in the CRC. In the morning of the inpatient study visit, the subject is
      brought into a state of severe hypoglycemia through IV administration of regular insulin
      diluted in normal saline. After a hypoglycemic state with plasma glucose &lt; 54 mg/dL (3
      mmol/L) is verified, the subject is administered a dose of G-Pen or Novo Glucagon via
      subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes
      post-dosing, with a value of &gt;70.0 mg/dL (3.89 mmol/L) or an increase of &gt; 20 mg/dL (&gt;1.11
      mmol/L) within 30 minutes of glucagon administration indicating a positive response. After 3
      hours, the subject is given a meal and discharged when medically stable. After a wash-out
      period of 7 to 28 days, subjects return to the CRC, and the procedures are repeated with each
      subject crossed over to the other treatment. A follow-up visit as a safety check is conducted
      2-7 days following administration of the final dose of study drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe Hypoglycemia Rescue</measure>
    <time_frame>At 30 minutes following administration of study drug</time_frame>
    <description>Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) or an increase in plasma glucose concentration &gt; 20 mg/dL (&gt; 1.11 mmol/L) within 30 minutes after administration of glucagon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Response 1</measure>
    <time_frame>At 30 minutes following a decision to administer study drug</time_frame>
    <description>Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) within 30 minutes of a decision to dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Response 2</measure>
    <time_frame>At 0-30 minutes following a decision to administer study drug</time_frame>
    <description>Number of subjects with an increase in plasma glucose concentration &gt; 20 mg/dL (&gt; 1.11 mmol/L) after administration of glucagon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration Time</measure>
    <time_frame>At 0-10 minutes from a decision to administer study drug</time_frame>
    <description>Mean time (minutes) to administer study drug from a decision to dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Resolution</measure>
    <time_frame>At 0-90 minutes following administration of study drug</time_frame>
    <description>Mean time (minutes) to complete resolution of the overall sensation of hypoglycemia from a decision to dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Insulin Hypoglycemia</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Severe Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>G-Pen followed by Novo Glucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novo Glucagon followed by G-Pen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen</intervention_name>
    <description>1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
    <arm_group_label>G-Pen followed by Novo Glucagon</arm_group_label>
    <arm_group_label>Novo Glucagon followed by G-Pen</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novo Glucagon</intervention_name>
    <description>1 mg subcutaneous injection of Novo Glucagon (glucagon injection)</description>
    <arm_group_label>G-Pen followed by Novo Glucagon</arm_group_label>
    <arm_group_label>Novo Glucagon followed by G-Pen</arm_group_label>
    <other_name>Glucagen Hypokit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and non-pregnant females diagnosed with type 1 diabetes (T1D) for at least 24
             months.

          2. Current usage of daily insulin treatment that includes having an assigned &quot;correction
             factor&quot; for managing hyperglycemia.

          3. Age 18 to 75 years, inclusive.

          4. Random serum C-peptide concentration &lt; 0.6 ng/mL.

          5. Willingness to follow all study procedures, including attending all clinic visits.

          6. Subject has provided informed consent as evidenced by a signed and dated informed
             consent form (ICF) completed before any trial-related activities occur.

        Exclusion Criteria:

          1. Pregnancy

          2. Glycated hemoglobin (HbA1c) &gt; 10% at Screening.

          3. Body mass index (BMI) &gt; 40 kg/m2.

          4. Renal insufficiency (serum creatinine greater than 3.0 mg/dL) or end-stage renal
             disease requiring renal replacement therapy.

          5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or
             greater than 3 times the upper limit of normal.

          6. Hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL.

          7. Hematocrit &lt; 30%.

          8. Blood pressure (BP) readings at Screening where systolic blood pressure (SBP) &lt; 90 or
             &gt; 150 mm Hg, and diastolic blood pressure (DBP) &lt; 50 or &gt; 100 mm Hg.

          9. Clinically significant electrocardiogram (ECG) abnormalities.

         10. Use of total insulin dose per day &gt; 2 U/kg.

         11. Inadequate venous access.

         12. Congestive heart failure, New York Heart Association (NYHA) class III or IV.

         13. History of myocardial infarction, unstable angina, or revascularization within the
             past 6 months.

         14. History of a cerebrovascular accident in the past 6 months or with major neurological
             deficits.

         15. Active malignancy within 5 years from Screening, except basal cell or squamous cell
             skin cancers. Any history of breast cancer or malignant melanoma will be exclusionary.

         16. Major surgical operation within 30 days prior to Screening.

         17. Current seizure disorder (other than with suspect or documented hypoglycemia).

         18. Current bleeding disorder, treatment with warfarin, or platelet count below 50 × 109
             per liter.

         19. History of pheochromocytoma or disorder with increased risk of pheochromocytoma
             (multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis, or Von Hippel-Lindau
             disease).

         20. History of insulinoma.

         21. History of allergies to glucagon or glucagon-like products, or any history of
             significant hypersensitivity to glucagon or any related products or to any of the
             excipients (DMSO and trehalose) in the investigational formulation.

         22. History of glycogen storage disease.

         23. Subject tests positive for human immunodeficiency virus (HIV), hepatitis C virus
             (HCV), or hepatitis B virus (HBV) infection (hepatitis B surface antigen positive
             [HBsAg+]) at Screening.

         24. Active substance other than tetrahydrocannabinol (THC) or alcohol abuse (more than 21
             drinks per week for male subjects or 14 drinks per week for female subject).

         25. Administration of glucagon within 7 days of Screening.

         26. Participation in other studies involving administration of an investigational drug or
             device within 30 days or 5 half-lives, whichever is longer, before Screening for the
             current study and during participation in the current study.

         27. Any other reason the Investigator deems exclusionary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPD-Las Vegas Clinical Research Unit</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz-Center for Medical Research</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Endocrinology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AltaSciences</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <results_first_submitted>March 26, 2020</results_first_submitted>
  <results_first_submitted_qc>March 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2020</results_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03738865/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03738865/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>132 subjects were randomized, however 1 subject withdrew prior to dosing, therefore 131 subjects received study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-Pen, Then Novo Glucagon</title>
          <description>Participants first received G-Pen 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received Novo Glucagon 1 mg subcutaneous injection</description>
        </group>
        <group group_id="P2">
          <title>Novo Glucagon, Then G-Pen</title>
          <description>Participants first received Novo Glucagon 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received G-Pen 1 mg subcutaneous injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Randomized Population</population>
      <group_list>
        <group group_id="B1">
          <title>G-Pen, Then Novo Glucagon</title>
          <description>Participants first received G-Pen 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received Novo Glucagon 1 mg subcutaneous injection.</description>
        </group>
        <group group_id="B2">
          <title>Novo Glucagon, Then G-Pen</title>
          <description>Participants first received Novo Glucagon 1 mg subcutaneous injection each. After a washout period of 7-28 days, they then received G-Pen 1 mg subcutaneous injection.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severe Hypoglycemia Rescue</title>
        <description>Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) or an increase in plasma glucose concentration &gt; 20 mg/dL (&gt; 1.11 mmol/L) within 30 minutes after administration of glucagon</description>
        <time_frame>At 30 minutes following administration of study drug</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>Participants received G-Pen 1 mg subcutaneous injection each.</description>
          </group>
          <group group_id="O2">
            <title>Novo Glucagon</title>
            <description>Participants received Novo Glucagon 1 mg subcutaneous injection each.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Hypoglycemia Rescue</title>
          <description>Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) or an increase in plasma glucose concentration &gt; 20 mg/dL (&gt; 1.11 mmol/L) within 30 minutes after administration of glucagon</description>
          <population>Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Response 1</title>
        <description>Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) within 30 minutes of a decision to dose</description>
        <time_frame>At 30 minutes following a decision to administer study drug</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>Participants received G-Pen 1 mg subcutaneous injection each.</description>
          </group>
          <group group_id="O2">
            <title>Novo Glucagon</title>
            <description>Participants received Novo Glucagon 1 mg subcutaneous injection each.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Response 1</title>
          <description>Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) within 30 minutes of a decision to dose</description>
          <population>Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Response 2</title>
        <description>Number of subjects with an increase in plasma glucose concentration &gt; 20 mg/dL (&gt; 1.11 mmol/L) after administration of glucagon.</description>
        <time_frame>At 0-30 minutes following a decision to administer study drug</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>Participants received G-Pen 1 mg subcutaneous injection each.</description>
          </group>
          <group group_id="O2">
            <title>Novo Glucagon</title>
            <description>Participants received Novo Glucagon 1 mg subcutaneous injection each.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Response 2</title>
          <description>Number of subjects with an increase in plasma glucose concentration &gt; 20 mg/dL (&gt; 1.11 mmol/L) after administration of glucagon.</description>
          <population>Intent-to-Treat Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Administration Time</title>
        <description>Mean time (minutes) to administer study drug from a decision to dose</description>
        <time_frame>At 0-10 minutes from a decision to administer study drug</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>Participants received G-Pen 1 mg subcutaneous injection each.</description>
          </group>
          <group group_id="O2">
            <title>Novo Glucagon</title>
            <description>Participants received Novo Glucagon 1 mg subcutaneous injection each.</description>
          </group>
        </group_list>
        <measure>
          <title>Administration Time</title>
          <description>Mean time (minutes) to administer study drug from a decision to dose</description>
          <population>Intent-to-Treat Population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.530"/>
                    <measurement group_id="O2" value="1.76" spread="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia Resolution</title>
        <description>Mean time (minutes) to complete resolution of the overall sensation of hypoglycemia from a decision to dose</description>
        <time_frame>At 0-90 minutes following administration of study drug</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>Participants received G-Pen 1 mg subcutaneous injection each.</description>
          </group>
          <group group_id="O2">
            <title>Novo Glucagon</title>
            <description>Participants received Novo Glucagon 1 mg subcutaneous injection each.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Resolution</title>
          <description>Mean time (minutes) to complete resolution of the overall sensation of hypoglycemia from a decision to dose</description>
          <population>Intent-to-Treat Population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.69" spread="7.428"/>
                    <measurement group_id="O2" value="15.32" spread="8.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for up to 5 weeks, from the time of consent through the follow-up visit.</time_frame>
      <desc>Treatment-Emergent Adverse Events (TEAE) Note: Some subjects experienced multiple adverse events. Consequently, the sum of the number of subjects experiencing each individual adverse events is greater than the number of unique subjects experiencing at least one adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>G-Pen</title>
          <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
        </group>
        <group group_id="E2">
          <title>Novo Glucagon</title>
          <description>Novo Glucagon: 1 mg subcutaneous injection of Novo Glucagon (glucagon injection)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Neither the Institution nor the principal investigator may submit for publication or presentation, the results of this trial without prior written consent of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chelsea Boundy</name_or_title>
      <organization>Xeris Pharmaceuticals, Inc.</organization>
      <phone>312-517-1466</phone>
      <email>cboundy@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

